Cite
HARVARD Citation
von der Lippe Gythfeldt, H. et al. (2020). Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER‐positive breast cancer. International journal of cancer. 147 (9), pp. 2515-2525. [Online].